Clinical Trials
108 trialsBiological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Impact of Arterial Partial Pressure of Oxygen on Anastomotic Leakage After Esophagectomy
Sun Yat-sen University
SCREEN-BE
University of Colorado, Denver
RATE
Centre of Postgraduate Medical Education
The Microbiome, Bile Acids, and Notch in Barrett's Esophagus (BE)
Columbia University
OPPOSITE
University Hospital Heidelberg
POWERRANGER
CancerCare Manitoba
CHARIOT
University of Oxford
EMERALD
City of Hope Medical Center
BETRNet2
Columbia University
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
MiMe-A
Jules Bordet Institute
Preoperative Marking of the Oral Resection Margin in Esophageal Cancer With a Surgical Fiducial Marker - First Experiences
Rigshospitalet, Denmark
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
City of Hope Medical Center
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
Hoosier Cancer Research Network
CARE-PRO
Istituto Oncologico Veneto IRCCS
Pembrolizumab in Refractory Advanced Esophageal Cancer
Dana-Farber Cancer Institute
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Alliance for Clinical Trials in Oncology
Endoscopic Mucosal Resection (EMR) in Barrett's Esophagus
Mayo Clinic
A Minimally-Invasive Sponge on a String Device for Screening for Barrett's Esophagus
Mayo Clinic
Mouthwash
Columbia University
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
Fox Chase Cancer Center
Influence of Central Obesity on the Esophageal Epithelial Barrier
Mayo Clinic
Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus
Columbia University
Cryotherapy -BEATS-RF Ablation Trial
Mayo Clinic
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
Translational Oncology Research International
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
CEBE
Johns Hopkins University
Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer
Rigshospitalet, Denmark
MATEO
AIO-Studien-gGmbH
Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus
UNICANCER
Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease
OHSU Knight Cancer Institute
Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
Swiss Cancer Institute
Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
Translational Oncology Research International
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Jonsson Comprehensive Cancer Center
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
Jonsson Comprehensive Cancer Center
Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer
Jonsson Comprehensive Cancer Center
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
Alliance for Clinical Trials in Oncology
Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer
Federation Francophone de Cancerologie Digestive
DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma
University of Oklahoma
PALAESTRA
Lund University Hospital
NeoRes
Karolinska University Hospital
Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach
Case Comprehensive Cancer Center
Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
Alliance for Clinical Trials in Oncology
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer
Northwestern University
Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Wake Forest University Health Sciences
Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Alliance for Clinical Trials in Oncology
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
City of Hope Medical Center
SiewertIIEAC
University of Bologna